For a generation of startups that raised Seed and Series A capital during the boom years, the path forward has bifurcated. The traditional "escalator" model of venture capital, where a Series A round leads predictably to a Series B growth round, followed by Series C scaling and an IPO, has broken down for the vast majority of market participants. In its place, a new phenomenon has emerged: the Series A Off-Ramp.

As the global healthcare sector approaches the 2026 fiscal year, the capital markets are poised for a definitive structural transformation. Following a tumultuous half-decade characterized by the exuberant highs of the Zero Interest Rate Policy (ZIRP) era and the subsequent liquidity crunch of 2022–2024, the IPO landscape has entered a phase of "Rational Exuberance." This new paradigm is defined not by the speculative fervour that drove the 2020–2021 vintage, but by a discipl

The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is currently navigating a period of profound structural transformation. For the better part of three decades, the provision of merger and acquisition (M&A) advisory services was the exclusive domain of career financiers, individuals whose expertise lay in financial engineering, balance sheet restructuring, and capital markets access, but who frequently lacked dire

The biggest European MedTech developments this week centre on the EU’s proposed overhaul of MDR/IVDR, a broader Commission health package to boost innovation and resilience, and continued capital formation for MedTech and digital health scale‑ups.  Together these moves signal a more innovation‑friendly regulatory path and fresh growth funding for European MedTech heading into 2026.​

The digital architecture of the United Kingdom's National Health Service (NHS) is currently executing a fundamental pivot, a transformation that marks the end of the "destination portal" era and the rise of the "aggregation engine." In this new ecosystem, patient portals are ceasing to be standalone destinations. Instead, they are evolving into "engines", sophisticated backend infrastructure layers that handle complex business logic (scheduling, triage, clinical correspondenc

This report argues that the feared "burst" of the healthcare AI bubble is not merely a cyclical downturn in venture sentiment but the mathematical inevitability of three converging forces: a regulatory cliff that imposes hardware-grade compliance costs on software startups, a maturation of financial obligations incurred during the peak of the hype cycle, and an operational "reality check" within health systems that is rapidly closing the window on the pilot-driven sales model

In an investment banking landscape often dominated by career financiers and generalist institutions, Nelson Advisors has cultivated a distinct identity rooted in the operational experience of its leadership. The firm’s "Founders for Founders" philosophy is not merely a marketing tagline but a fundamental operational differentiator that dictates its approach to client selection, deal structuring and negotiation strategy.

The global healthcare landscape is rapidly converging upon a singular, undeniable crisis point regarding musculoskeletal (MSK) health, creating a definitive "before and after" scenario centered around the year 2026. For decades, MSK disorders, encompassing conditions ranging from non-specific low back pain (LBP) to complex post-surgical rehabilitation, have served as the silent epidemic of the industrialised world. However, as we approach the latter half of the 2020s, the con

The Specialist Boutiques: Firms like Nelson Advisors and Clipperton offer highly targeted, domain-specific expertise. They often cater to founder-led exits and specific verticals like Health IT, MedTech, and AI, providing a level of operational empathy and sector nuance that larger firms cannot provide.

European HealthTech this week is dominated by EU-level moves to unlock health data for AI, ongoing NHS digital transformation in the UK, and continued momentum around EU‑wide digital health initiatives and summits.​ European MedTech this week is defined by three themes: regulatory moves around data and devices, imaging and diagnostics innovation (largely via RSNA spillover), and fresh capital forming for growth-stage and infrastructure-heavy plays in Europe.​

Nelson Advisors Partner Lloyd Price has been invited to Judge the PitchFest Awards at ReWired 2026. This is the third time Lloyd has judged the prestigious awards, highlighting the pedigree of UK Digital Health and MedTech companies. Unlike standard "demo days," PitchFest is specifically designed to break down the barriers between start-ups and the NHS. The judges are not just venture capitalists but also Chief Information Officers (CIOs) and Chief Clinical Information Office

Nelson Advisors invited to Chair the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare' Panel at Health Tech Forward 2025 Nelson Advisors Partner Lloyd Price Chaired the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare panel' at Health Tech Forward 2025 in Barcelona this week. The  panel focused around 5 main questions debated by the guests Laura, Alberto and Naoufal. 1) Laura Busquet Raich, Head of Data Protection and ComplianceConsorci de Sa

Nelson Advisors Partner Lloyd Price was invited to Chair the discussions at the IESE Business School Healthcare Club event on the 3rd December in Barcelona. Lloyd was joined on the panel by Javier Matacàs, Investment Director at Careventures and ⁠Ilan Misano, CEO of X-Applied and former Head of the StartUp Growth Lab - Google Israel's startup accelerator.

The European healthcare technology landscape is currently navigating a period of profound structural transformation. Historically characterised by extreme fragmentation, a patchwork of national regulations, localised reimbursement models and legacy on-premise software, the sector has become the primary target for a new breed of operator: the "Platform Consolidator." Bending Spoons, an Italian technology company, has become the archetype for this model in the consumer app spac

The United Kingdom’s Healthtech and Medtech sectors are approaching a definitive inflection point as the market transitions into 2026. Following a period characterised by post-pandemic market corrections, valuation compression and capital scarcity between 2023 and 2025, the outlook for 2026 is one of strategic acceleration and structural evolution. This report predicts that 2026 will not merely represent a cyclical rebound but a fundamental shift in the operating logic of